[
  {
    "ts": null,
    "headline": "A Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.",
    "summary": "Some half a million cases of Lyme disease occur each year in the U.S., plus another 130,000 in Europe.",
    "url": "https://finnhub.io/api/news?id=1a5bc22d3a6b5eedbe83a95ccb0545756fd879689193de2cc8d2ff1ef08c158a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757461680,
      "headline": "A Lyme Disease Vaccine’s Final Test Results Could Appear By Yearend.",
      "id": 136689358,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Some half a million cases of Lyme disease occur each year in the U.S., plus another 130,000 in Europe.",
      "url": "https://finnhub.io/api/news?id=1a5bc22d3a6b5eedbe83a95ccb0545756fd879689193de2cc8d2ff1ef08c158a"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
    "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
    "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757451534,
      "headline": "Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2025 Update",
      "id": 136680992,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1264256639/image_1264256639.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "See an update on Prem Watsa's latest 13F portfolio moves, find out his top stock picks, global strategy, and key insights for focused, long-term investing.",
      "url": "https://finnhub.io/api/news?id=628bb2894b5e7b55dcceee727c68da960b38694f77e54a37375520f34a37c29b"
    }
  },
  {
    "ts": null,
    "headline": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
    "summary": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
    "url": "https://finnhub.io/api/news?id=56d1c6faf012dba34535f5130275db2e14159cb2a66a5480546ddc9c76eca231",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757448000,
      "headline": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
      "id": 136715136,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women",
      "url": "https://finnhub.io/api/news?id=56d1c6faf012dba34535f5130275db2e14159cb2a66a5480546ddc9c76eca231"
    }
  },
  {
    "ts": null,
    "headline": "Will LLY's Oncology Portfolio Provide Key Diversification Benefits?",
    "summary": "Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.",
    "url": "https://finnhub.io/api/news?id=1c5055be8f07e03450784c1fc367be823dcd3887dc84bcce36a14fc76eb64cf6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757434860,
      "headline": "Will LLY's Oncology Portfolio Provide Key Diversification Benefits?",
      "id": 136688960,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.",
      "url": "https://finnhub.io/api/news?id=1c5055be8f07e03450784c1fc367be823dcd3887dc84bcce36a14fc76eb64cf6"
    }
  },
  {
    "ts": null,
    "headline": "Why The Market Is Dangerously Wrong About Pfizer Stock",
    "summary": "Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum. Click here to find out why PFE stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=f1a7a36c8624943a2d85e3bd1cfa52007f7b78f3f3bbbad256db4d7fc5c800b5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757433781,
      "headline": "Why The Market Is Dangerously Wrong About Pfizer Stock",
      "id": 136679194,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum. Click here to find out why PFE stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=f1a7a36c8624943a2d85e3bd1cfa52007f7b78f3f3bbbad256db4d7fc5c800b5"
    }
  },
  {
    "ts": null,
    "headline": "Anxiety Disorders and Depression Treatment Market Growth Trends Report 2025-2033 | Pharmacological and Non-Pharmacological Innovations Strengthen Global Mental Health Support and Treatment Options",
    "summary": "The Anxiety Disorders and Depression Treatment Market is poised for significant growth, escalating from USD 20.51 billion in 2024 to USD 34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Innovations in pharmacological treatments, with",
    "url": "https://finnhub.io/api/news?id=b35e65e905565ca7735d8543f14bf4c252432907d9ec754afb8a3ffe9f68c09d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757431440,
      "headline": "Anxiety Disorders and Depression Treatment Market Growth Trends Report 2025-2033 | Pharmacological and Non-Pharmacological Innovations Strengthen Global Mental Health Support and Treatment Options",
      "id": 136688673,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Anxiety Disorders and Depression Treatment Market is poised for significant growth, escalating from USD 20.51 billion in 2024 to USD 34.31 billion by 2033, driven by rising mental health awareness, global stress levels, and advancements in therapies. Increased adoption of digital therapeutics and telemedicine is enhancing access and reducing stigma, with notable interventions such as India’s Tele MANAS offering nationwide psychiatric services. Innovations in pharmacological treatments, with",
      "url": "https://finnhub.io/api/news?id=b35e65e905565ca7735d8543f14bf4c252432907d9ec754afb8a3ffe9f68c09d"
    }
  },
  {
    "ts": null,
    "headline": "Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies",
    "summary": "CAMBRIDGE, Mass., September 09, 2025--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.",
    "url": "https://finnhub.io/api/news?id=a0ba38c0d10020d162034920906f6a3aa6e51e063d0497a1283c551f40c49dd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757424600,
      "headline": "Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies",
      "id": 136689334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, Mass., September 09, 2025--Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, today announced the appointment of Dr. Richard Fahrner as Chief Technology Officer and Dr. Tamara Agajanov, MD, as Senior Vice President – Clinical Development.",
      "url": "https://finnhub.io/api/news?id=a0ba38c0d10020d162034920906f6a3aa6e51e063d0497a1283c551f40c49dd8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's PREVNAR 20 Selected for Pneumococcal Public Immunization Program in British Columbia",
    "summary": "Today, Pfizer Canada ULC announced that its 20-valent pneumococcal conjugate vaccine, PREVNAR 20, has been selected for the publicly funded pneumococcal immunization program in the Canadian province of British Columbia (BC). This program, launched in July 2025, includes routine immunizations of pediatric and older adult populations, as well as high-risk adult and pediatric populations.",
    "url": "https://finnhub.io/api/news?id=8d68b626dbf744e14020a18fe875d3e306056273d863692a581caab9573baaab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757422800,
      "headline": "Pfizer's PREVNAR 20 Selected for Pneumococcal Public Immunization Program in British Columbia",
      "id": 136689362,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Today, Pfizer Canada ULC announced that its 20-valent pneumococcal conjugate vaccine, PREVNAR 20, has been selected for the publicly funded pneumococcal immunization program in the Canadian province of British Columbia (BC). This program, launched in July 2025, includes routine immunizations of pediatric and older adult populations, as well as high-risk adult and pediatric populations.",
      "url": "https://finnhub.io/api/news?id=8d68b626dbf744e14020a18fe875d3e306056273d863692a581caab9573baaab"
    }
  },
  {
    "ts": null,
    "headline": "The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now",
    "summary": "With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.",
    "url": "https://finnhub.io/api/news?id=81207b614505ab7a47686052e99288343a9698c53d12f76f6a1d52c01f7904c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757415900,
      "headline": "The Best Ultra-High-Yield Dividend Stock to Invest $1,000 in Right Now",
      "id": 136689363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With a 6.2% yield, this high yielder is focused on supporting the innovation that drives the healthcare industry forward.",
      "url": "https://finnhub.io/api/news?id=81207b614505ab7a47686052e99288343a9698c53d12f76f6a1d52c01f7904c5"
    }
  },
  {
    "ts": null,
    "headline": "Concussions Market Research Report 2025-2035 | Epidemiological Analysis, Key Market Trends, Patent Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics",
    "summary": "The concussions market is experiencing significant growth due to increased awareness of the long-term impacts of mild traumatic brain injuries and advancements in diagnostic technology. Fueled by advances like biomarker assays and portable neuroimaging tools, this sector benefits from investments in research and digital health. North America leads the market, backed by robust healthcare infrastructure and strategic regulations. Key players such as Oragenics, Pfizer, and Sanofi are optimizing the",
    "url": "https://finnhub.io/api/news?id=3c36d159f8cf23e6275776abed59616c302cdb7d6022f9d32ce4a5d6ecb8c62a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757415180,
      "headline": "Concussions Market Research Report 2025-2035 | Epidemiological Analysis, Key Market Trends, Patent Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics",
      "id": 136689364,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The concussions market is experiencing significant growth due to increased awareness of the long-term impacts of mild traumatic brain injuries and advancements in diagnostic technology. Fueled by advances like biomarker assays and portable neuroimaging tools, this sector benefits from investments in research and digital health. North America leads the market, backed by robust healthcare infrastructure and strategic regulations. Key players such as Oragenics, Pfizer, and Sanofi are optimizing the",
      "url": "https://finnhub.io/api/news?id=3c36d159f8cf23e6275776abed59616c302cdb7d6022f9d32ce4a5d6ecb8c62a"
    }
  },
  {
    "ts": null,
    "headline": "USA Vaccine Market Outlook Report 2025-2030 | Focus on Lassa Fever, Ebola, RSV Vaccines, Alongside Genomics-Driven Targeted Therapies, Strengthens Public Health Preparedness and Investment Potential",
    "summary": "The USA vaccine market is valued at USD 30 billion, driven by health initiatives, disease awareness, and tech advancements. Pfizer, Moderna, and Johnson & Johnson lead, benefiting from R&D prowess and distribution. Growth is spurred by government funding and emerging vaccine innovation, despite challenges like hesitancy and supply disruptions.Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The \"USA Vaccine Market outlook to 2030\" report has been added to ResearchAndMarkets.com's offering.The USA vacc",
    "url": "https://finnhub.io/api/news?id=01b26b6d1e3a658e5fc5e6bd543ec22d3ebf9d02471ad137d9b2234ecaf9ab3c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757413260,
      "headline": "USA Vaccine Market Outlook Report 2025-2030 | Focus on Lassa Fever, Ebola, RSV Vaccines, Alongside Genomics-Driven Targeted Therapies, Strengthens Public Health Preparedness and Investment Potential",
      "id": 136688676,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The USA vaccine market is valued at USD 30 billion, driven by health initiatives, disease awareness, and tech advancements. Pfizer, Moderna, and Johnson & Johnson lead, benefiting from R&D prowess and distribution. Growth is spurred by government funding and emerging vaccine innovation, despite challenges like hesitancy and supply disruptions.Dublin, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The \"USA Vaccine Market outlook to 2030\" report has been added to ResearchAndMarkets.com's offering.The USA vacc",
      "url": "https://finnhub.io/api/news?id=01b26b6d1e3a658e5fc5e6bd543ec22d3ebf9d02471ad137d9b2234ecaf9ab3c"
    }
  },
  {
    "ts": null,
    "headline": "Crypto Stock Market Gambles Are Paying Off. Why That Luck Won’t Last.",
    "summary": "Crypto Stock Market Gambles Are Paying Off. Why That Luck Won’t Last.",
    "url": "https://finnhub.io/api/news?id=e0329c11680575b8acdce4f04bca44e5458fab10fe3d8d81f7fb634196beb117",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757399820,
      "headline": "Crypto Stock Market Gambles Are Paying Off. Why That Luck Won’t Last.",
      "id": 136715158,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Crypto Stock Market Gambles Are Paying Off. Why That Luck Won’t Last.",
      "url": "https://finnhub.io/api/news?id=e0329c11680575b8acdce4f04bca44e5458fab10fe3d8d81f7fb634196beb117"
    }
  }
]